Aurobindo Pharma Limited — Important, 20-02-2025: Updates

The US FDA conducted an inspection at Aurobindo Pharma USA Inc.'s warehouse in East Windsor, New Jersey, revealing five observations and classifying the facility as 'Official Action Indicated (OAI).' However, the company does not anticipate any business impact from this classification. Aurobindo Pharma is committed to working closely with the FDA and enhancing compliance continuously. This development highlights the company's proactive approach in maintaining regulatory standards, but investors should monitor the situation closely for any future implications on operations.